Mezzion Pharma Co.,Ltd.
Financials
Valuation Metrics
Mezzion Pharma Co.,Ltd.'s Market Cap is ₩1.7T. At end of 2025 it was ₩2.8T. Ranked #227 of 2,436 in KR market (top 9%), #49 of 1,649 on KOSDAQ (top 3%), #22 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.66T KRW | KR#227/2,436 Sec#22/234 |
| Revenue | 7.97B KRW | KR#2,307/2,436 Sec#184/234 |
| Net Income | -36.93B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 98.92B KRW | KR#1,750/2,436 Sec#141/234 |
| Net Assets | 15.51B KRW | KR#2,326/2,436 Sec#220/234 |
| Employees | 18 | KR#2,234/2,436 Sec#208/234 |
| Value | ||
| P/B | 107.34x | KR#2,406/2,436 Sec#229/234 |
| P/S | 208.86x | KR#2,400/2,436 Sec#218/234 |
| FCF Yield | -1.00% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROA | -37.33% | KR#2,335/2,436 Sec#213/234 |
| Op. Margin | -223.45% | KR#2,344/2,436 Sec#188/234 |
| Revenue Growth | 3.19% | KR#1,260/2,436 Sec#117/234 |
| Financial Health | ||
| Debt Ratio | 637.75% | KR#2,324/2,436 Sec#227/234 |
| Total Debt | 10.56B KRW | KR#1,609/2,436 Sec#146/234 |
| FCF | -16.73B KRW | KR#1,859/2,436 Sec#175/234 |
| Cash | 17.42B KRW | KR#1,325/2,436 Sec#103/234 |
| Current Ratio | 0.47x | KR#2,271/2,436 Sec#219/234 |
| Performance | ||
| 1Y Return | 44.49% | KR#265/2,436 Sec#23/234 |
| 1M Return | -9.18% | KR#1,710/2,436 Sec#171/234 |
| From 52W High | -69.76% | KR#2,127/2,436 Sec#191/234 |
| 1Y MDD | -70.47% | KR#1,969/2,436 Sec#171/234 |
| Trading | ||
| Volume | 581,583 shares | KR#243/2,436 Sec#20/234 |
| Foreign Own. | 25.03% | KR#159/2,436 Sec#5/234 |
| Per Share | ||
| EPS | -1,222 KRW | KR—/2,436 Sec—/234 |
| BPS | 510 KRW | KR#2,389/2,436 Sec#227/234 |
Company Info
Mezzion, established in 2002, is a KOSDAQ-listed pharmaceutical manufacturing and sales corporation. The company develops various new drugs, including treatments for erectile dysfunction and benign prostatic hyperplasia, and has licensed out and exported products to major countries such as the United States. Recently, Mezzion has focused on developing a single ventricle disease treatment, having received FDA approval for an additional clinical protocol in 2023 and currently proceeding with further clinical trials. The company is headquartered in Gangnam-gu, Seoul.